Of the 31 advanced hepatocellular carcinoma
patients treated with the drug, 28 were evaluable and 14 completed the 6 month duration of the study.
The most common liver tumor is hepatocellular carcinoma
(HCC) accounting for 80% of total primary tumors followed by cholangiocarcinoma4.
Researchers reported on their analysis of past prevalence of HCV, NASH, and alcoholic cirrhosis and prediction of future trends and their effect on hepatocellular carcinoma
10,278,960 entitled "Sphingosine Pathway Modulating Compounds for the Treatment of Cancers" that is directed to methods for treating hepatocellular carcinoma
, the most common human liver cancer, using the compound Ozanimod.
Biopharmaceutical firms LSK BioPharma and Jiangsu Hengrui Medicine Co Ltd (SHA:600276) on Monday jointly announced US FDA clearance to launch a clinical trial in advanced hepatocellular carcinoma
(HCC) patients in the US.
DIRECT-ACTING ANTIVIRALS significantly decrease risk of hepatocellular carcinoma
and mortality in persons with hepatitis C, according to results of the first prospective, longitudinal study to evaluate the effect of the drugs on complications related to the infection.
announced today that presentations on a series of abstracts highlighting the latest data from post-hoc analyses of a Phase III clinical study (REFLECT/Study 304) on its in-house discovered multiple receptor tyrosine kinase inhibitor lenvatinib mesylate (product name: Lenvima, "lenvatinib") as first-line treatment for unresectable hepatocellular carcinoma
(HCC) will be presented during the 2019 Gastrointestinal Cancers Symposium (ASCO-GI) in San Francisco from January 17 to 19.
(HCC) accounts for one-fifth of the most common cancers worldwide.
Fibrolamellar carcinoma (FLC) is a unique primary hepatocellular malignancy, encompassing patient demographics, risk factors, and tumor markers distinct from those of classical hepatocellular carcinoma
[2.] Khalaf N, Ying J, Mittal S, et al Natural history of untreated hepatocellular carcinoma
in a US C ohort and the role of cancer surveillance.
Objective: To determine the diagnostic accuracy of Glypican-3 in differentiating hepatocellular carcinoma
from metastatic liver tumours while taking histopathology as the gold standard.
FRIDAY, July 6, 2018 (HealthDay News) -- Cabozantinib results in significantly longer overall and progression-free survival than placebo among patients with advanced hepatocellular carcinoma
, according to a study published in the July 5 issue of the New England Journal of Medicine.